Back

Remnant cholesterol, not LDL cholesterol, explains peripheral artery disease risk conferred by apolipoprotein B: a cohort study

1 September 2024 (17:00 - 17:12)
Organised by: Logo
Congress Presentation Part of: Cardiovascular treatment: protecting the brain and the limbs Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Benjamin Nilsson Wadstrom

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

4 More presentations in this session

Presentation thumbnail
The evolution of carotid atherosclerotic plaque composition: a prospective study
Mr L. Zuo (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Extracranial systemic embolic events in patients with atrial fibrillation: an individual patient-level meta-analysis of 71 683 patients randomized to NOAC vs warfarin from the COMBINE-AF study
Doctor S. Al Said (Boston, US)
Abstract Slides Video
Presentation thumbnail
The influence of concomitant antiplatelet therapy in venous thromboembolism patients treated with anticoagulants in the DOAC era: insight from the COMMAND VTE Registry-2
Doctor K. Kaneda (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Drug-eluting devices versus angioplasty in infrapopliteal artery disease:an updated systematic review and meta-analysis
Mr E. Katsuyama (Santo Andre, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular treatment: protecting the brain and the limbs
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 17:00 CET
You may be interested in
thumbnail
Congress Presentation
Elevated remnant cholesterol in atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study
thumbnail
Congress Presentation
Independent causal effect of remnant cholesterol on atherosclerotic cardiovascular outcomes: a Mendelian randomization study
thumbnail
Congress Presentation
Elevated remnant cholesterol confers high risk of ASCVD without prompting lipid-lowering therapy: an unmet medical need

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources